At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 11 enrolled
Drug / intervention
VentaProst (inhaled epoprostenol delivered via a dedicated delivery system)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of VentaProst (Inhaled Epoprostenol Delivered Via Dedicated Delivery System) in Subjects With COVID-19 Requiring Mechanical Ventilation
In Brief
A Phase 2 clinical trial evaluating VentaProst (inhaled epoprostenol delivered via a dedicated delivery system) for COVID-19. Completed, enrolled 11 participants across 1 site.
Detailed Summary
The purpose of this study is to investigate whether inhaled epoprostenol given via a breath actuated delivery system will help improve oxygen levels and treatment outcomes in patients with COVID-19 who are on mechanical ventilation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesUnited States
CollaboratorsOhio State University
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedJun 2020
Enrollment StartSep 2020
Primary CompletionJun 2021
TodayJul 2026
First PostedJun 30, 2020
Enrollment StartSep 15, 2020
Primary CompletionJun 29, 2021
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 6.0 years ago
Interventions
VentaProst (inhaled epoprostenol delivered via a dedicated delivery system)drug
VentaProst delivered for up to 10 days via mechanical ventilation at a dose range that may be up or down titrated to a patient's clinical condition.